The present study showed that an SGLT2 inhibitor, canagliflozin, increased the average FABP4 level by 10.3% in patients with type 2 diabetes mellitus, though FABP4 level was reduced in 33.3% of the studied patients. The gene discussed is FABP4; the disease is diabetes mellitus.